Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Interneuron Pharmaceuticals Inc.

(IPIC)

Business: Neuroscience

Davis Temple of Stover Haley Burns said it is likely that IPIC's dexfenfluramine for

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE